1. Ganesh Padhi (B047)Richansh Kumar(B038)Ritesh Kamal(B032)Sushant Kumar(B039)Mayank Shukla(B055)B Kushal Kumar(B036)

2. Pharmaceutical sector United States-largest market with $289 billion annualsales EU and Japan are the next big markets in sales Markets like china, south Korea ,Russia and Mexico aregrowing at 81%. India- 3rd largest producer, Cardiovascular-50% &Diabetes -22%,Projected growth - $ 77 billion by 2012 3. Progress towards health-related MDGs Eradication of Hunger Improvement innutrition of undernourished children Reduction in Child Mortality at 2.7% everyyear Maternal Mortality Ratio(MMR) decreased by34% Fighting HIV/AIDS, tuberculosis and malaria 4. Contd Increase in population with better sanitation andsafe drinking water from 77% to 87% Better access to affordable essential medicines indeveloping countries 5. TransparencyPublicCorruption private partnerships Ethical promotion Quality ofandmedicines marketingIssues in Pricingdiscountspharma Clinical trails andsectordonationsManagement Patents and, Monitoring licenses andAccountabilit Policyy Neglected influenceMedicines fordiseases Advocacydisadvantaged individuals andandlobbying community 6. About Astrazeneca Worlds fifth largest pharmaceutical company Dedicated to research, development , manufacturingand marketing of medicines in over 100 countries. Committed to sustainable development of business 7. Astrazenecas CSR approach Stakeholder based approach Mainly targeted employees Other stakeholders were suppliers, global community, environment and customers. 8. Employees Workforce diversity Work-life balance Safety, health and well being Health screening and other health activities 9. Suppliers Continuing risk assessments of suppliers Rolling out a programme of onsite audits of keysuppliers Implementing plans to improve standards with certainsuppliers Following up and verifying that progress is being madewith suppliers Training staff on their standards 10. Customers Access to medicines for vulnerable individuals AstraZenecas Young Health Programme for 10-19years of children Community sponsorships and charitable donations Patient assistance programmes to avail medicines freeor at reduced prices. 11. OthersGlobal community Disaster reliefEnvironment Reduction in Greenhouse gas footprint Waste reduction Reduction in water usage Product environmental improvement Improvement in supply chain 12. Critical analysis Stakeholder approach Business responsibilities 13. Stakeholder approach Employees given more importance Suppliers have been maintained properly by adheringto global standards Some activities favoring environmental sustainability Special focus on access to medicines for needy anddisadvantaged individuals Very few activities for global community and almostnothing for the local community 14. Business responsibilities Economic responsibilities successful Legal responsibilities fulfilled to considerable extent Ethical responsibilities few activities ,needs toimplement more activities and take it to a large scale Philanthropic responsibilities nothing spectaculardone as of yet 15. Conclusion Addresses concerns of majority of stakeholders Needs to work more towards suppliers and localcommunity More of strategic CSR initiatives than philanthropicactivities 16. Scope for future work Work environment improvement for employees Awareness programme for suppliers regardingenvironmental sustainability Implement environmental activities at a larger scale inmore areas Invest more in R&D for innovative drugs andtechniques for treatment Participate in community beneficial activities.